Skip to content

Study · Animal study (in vivo) · rat · 2008

3 results

Geroprotective effect of ala-glu-asp-gly peptide in male rats exposed to different illumination regimens.

Vinogradova IA, Bukalev AV, Zabezhinski MA, Semenchenko AV, Khavinson VKh, Anisimov VN

Bulletin of experimental biology and medicine1 Apr 2008Cited by 4 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, epithalone virtually did not change the mean lifespan.

    In plain wordsIn rats, epithalone virtually did not change the average lifespan.

    Peptide
    Epitalon
    Outcome
    No significant changeMean lifespan
    Study

    ratn: not reported in source

    Male rats under standard, natural or constant illumination
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    0.1 microg/rat 5 times a week · subcutaneous · from the age of 4 months until natural deathAs given in this study (rat).

    Source sentences

    Summary
    virtually did not change the mean lifespan of male rats
    1 context sentence
    Summary · context
    Exposure of male rats to permanent or natural illumination of North-Western Russia accelerated their death in comparison with animals exposed to standard (12 h) light.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male rats under natural or constant illumination, epithalone was associated with a significant normalization of population aging rate and of mortality rate doubling time.

    In plain wordsIn rats kept under natural or constant light, epithalone was linked to a more normal aging rate and mortality rate doubling time.

    Peptide
    Epitalon
    Outcome
    Not applicablePopulation aging rate and mortality rate doubling time
    Study

    ratn: not reported in source

    Male rats under standard, natural or constant illumination
    Outcome group
    Aging markers · Aging and longevity
    Studied dose
    0.1 microg/rat 5 times a week · subcutaneous · from the age of 4 months until natural deathAs given in this study (rat).

    Source sentences

    Summary
    was associated with a significant (p<0.05) normalization of population aging rate and hence, time of mortality rate doubling in groups exposed to natural or constant illumination.
    1 context sentence
    Summary · context
    Exposure of male rats to permanent or natural illumination of North-Western Russia accelerated their death in comparison with animals exposed to standard (12 h) light.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In male rats under any photoregimen, epithalone significantly inhibited the development of spontaneous tumors, mainly testicular leydigomas and leukemias.

    In plain wordsIn rats, epithalone reduced the development of spontaneous tumors, mainly testicular leydigomas and leukemias, under all light regimens.

    Peptide
    Epitalon
    Outcome
    DecreaseSpontaneous tumor development
    Study

    ratn: not reported in source

    Male rats under standard, natural or constant illumination
    Outcome group
    Tumor growth · Cancer
    Studied dose
    0.1 microg/rat 5 times a week · subcutaneous · from the age of 4 months until natural deathAs given in this study (rat).

    Source sentences

    Summary
    Epithalone injected to rats exposed to any photoregimen significantly inhibited the development of spontaneous tumors, primarily testicular leydigomas and leukemias.
    1 context sentence
    Summary · context
    Exposure of male rats to permanent or natural illumination of North-Western Russia accelerated their death in comparison with animals exposed to standard (12 h) light.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.